Last reviewed · How we verify
NCT06248710: DOT
Dog Presence and Oxytocin on Trust Towards Therapists
Phase 2, PHASE3 trial testing Oxytocin nasal spray in Depressive Symptoms in 176 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Dr. Karin Hediger |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 176 |
| Start date | 29 January 2024 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Oxytocin nasal spray — full drug profile →
- Animal-Assisted Intervention
- Placebo
Conditions studied
- Depressive Symptoms — all drugs for Depressive Symptoms →
- Human-Animal Interaction — all drugs for Human-Animal Interaction →
Sponsor
Dr. Karin Hediger
Who can join
18 and older, any sex, with Depressive Symptoms or Human-Animal Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Oxytocin has been proposed as a neuroendocrine mechanism that may mediate the relationship between dog ownership and positive health outcomes and be linked to human-dog interactions and is thought to be a mechanism of interspecies bonding. While the role of oxytocin in human bonding behaviours and social behaviour, in general, is becoming well-established the role of oxytocin in human-animal interaction and Animal-Assisted Interventions (AAI) remains unclear. This research gap calls for more high-quality research investigating this possible neuroendocrine underlying mechanism to advance knowledge about AAI. If oxytocin indeed might be involved in interspecies bonding, intranasally administered oxytocin should not only enhance trust toward a human but also towards a dog.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06248710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oxytocin nasal spray
Trials testing the same drug.
- NCT07162584 — Oxytocin and Human Defensive Responses in a Dynamic Situation · NA · recruiting
- NCT06194851 — Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD · Phase 2 · recruiting
- NCT05934812 — Intranasal Oxytocin in Youth With Autism · Phase 2 · not yet recruiting
- NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
- NCT06332066 — Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness · Phase 1 · unknown
Other recruiting trials for Depressive Symptoms
Currently open trials in the same condition.
- NCT07299903 — IMB-Based Sleep Hygiene Education for Menopausal Women: Effects on Sleep Quality and Depression · NA · recruiting
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
- NCT07241325 — Psychological Well-Being, Depression, and Health-Related Quality of Life in Adults With Type 2 Diabetes: A Cross-Section · recruiting
- NCT07216326 — Our Voices Matter: Intervention for Depression in Youth · NA · recruiting
Other Dr. Karin Hediger trials
Trials by the same sponsor.
- NCT05837546 — Neurodynamic of the Human Brain Underlying Animal-assisted Intervention in Healthy Adults · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06248710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Karin Hediger
- Last refreshed: 5 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06248710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing